Factor XIII: Inherited and acquired deficiency

Blood Reviews

Volumn 7, Issue 4, 1993, Pages 229-242

  Board, P G ^a   Lososky, M S ^b   Miloszewski, K J A ^b  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR 13 CONCENTRATE; CALCIUM; ENZYME PRECURSOR; FIBRIN; FIBRONECTIN; THROMBIN;

ANAPHYLACTOID PURPURA; AUTOSOMAL RECESSIVE INHERITANCE; BLEEDING TENDENCY; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BRAIN HEMORRHAGE; COLITIS; ENZYME ACTIVATION; ENZYME SUBUNIT; EROSIVE GASTRITIS; FIBRINOLYSIS; FIBROBLAST; FRACTURE HEALING; HEMOSTASIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MONOCYTE; MORTALITY; PRIORITY JOURNAL; PROTEIN CROSS LINKING; REVIEW; THROMBOCYTE; WOUND HEALING;

AMINO ACID SEQUENCE; ENZYME ACTIVATION; FACTOR XIII; FACTOR XIII DEFICIENCY; FIBRIN; HEMORRHAGIC DISORDERS; HEMOSTASIS; HUMAN; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; WOUND HEALING;

EID: 0027729953     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0268-960X(93)90010-2     Document Type: Article

References (185)

1. Zur Frage der Reversibilitat der Fibringerinnung II
2. Calcium and blood coagulation
3. The fibrinolytic activity of hemolytic streptococci
4. A study on the conversion of fibrinogen to fibrin
5. On the solubility of fibrin clots
6. Fibrin clots. Some properties on the ‘serum factor’
7. Contributions to the fibrinogen fibrin problem. (Fibrin stabilizing factor — FSF)
8. O stabilizacji wloknika czyli trzeciej fazie fibrynogenezy
9. Fibrinase. I. Purification of substrate and enzyme
10. Fibrinase. II. Some physical properties
11. Fibrinase. III. Some enzymatic properties
12. Fibrinase. IV. Effect on fibrin solubility
13. Conversion of fibrin to desmofibrin
14. A new class of blood coagulation inhibitors
15. Specific inhibitors and the chemistry of fibrin polymerisation
16. Transglutaminase activity of the fibrin crosslinking enzyme
17. Lysine as amine donor in fibrin crosslinking
18. ε(γ-glutamyl)lysine, crosslink of polymerised fibrin
19. Identification of isopeptide crosslinks in insoluble fibrin
20. Chain pairs in the crosslinking of fibrin
21. Subunit structure of human fibrinogen, soluble fibrin and crosslinked insoluble fibrin
22. Crosslinking of rabbit fibrin in vivo
23. Formation of the ε(γ-glutamyl)lysine crosslink in hair proteins. Investigation of transamidases in hair follicles
24. The identification of εN-(γ-glutamyl)-l-lysine crosslinks in native wool keratins
25. Isolation, purification and characterisation of bovine epidermal transglutaminase
26. Factor XIII activation and interactions
27. Contribution of fibrin stabilization to clot strength
28. Accelerated lysis of blood clots
29. A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilising factor deficiency
30. Human factor XIII: Fibrin-Stabilizing Factor
31. Fibrin stabilisation and factor XIII deficiency
32. Intracranial hemorrhage in congenital deficiency of Factor XIII
33. Congenital Factor XIII deficiency: a case report and review of literature
34. Congenital Factor XIII deficiency. A family report
35. Clinical aspects of congenital coagulation Factor XIII deficiency
36. Experience in the long term prophylactic therapy of four patients with congenital Factor XIII deficiency
37. Fibrin stabilizing factor (FSF)
38. Human factor XIII from plasma and platelets
39. Genetic polymorphism of the A subunit of human coagulation factor XIII
40. Genetic polymorphism of the B subunit of human coagulation factor XIII
41. b-Chains prevent the proteolytic inactivation of the a-chains of plasma Factor XIII
42. Characterization of the kinetic pathway for fibrin promotion of α-thrombincatalyzed activation of plasma Factor XIII
43. Interactions of Factor XIII with fibrin as a substrate and cofactor
44. Demonstration of Factor XIII in human megakaryocytes by a fluorescent antibody technique
45. Identification of intracellular Factor XIII in human monocytes and macrophages
46. FXIII of blood coagulation in human monocytes
47. Identification of blood coagulation Factor XIII in human peritoneal monocytes
48. Comparative studies on the fibrin stabilizing factors from human plasma, platelets and placentas
49. Amino acid sequence studies of Factor XIII and the peptide released during its activation by thrombin
50. Amino acid sequence of the a subunit of human Factor XIII
51. Characterization of cDNA coding for human Factor XIIIa
52. Primary structure of blood coagulation Factor XIIIa (fibrinoligase, transglutaminase) from human placenta
53. Localization of the coagulation Factor XIIIA subunit gene (FI3A) to chromosome bands 6p24 〉 p25
54. The ε-(γ-glutamyl)lysine crosslink and the catalytic role of transglutaminases
55. The amino acid sequence around the reactive cysteine residue in human plasma Factor XIII
56. Primary structure of keratinocyte transglutaminase
57. Amino acid sequence of guinea pig liver transglutaminase from its cDNA sequence
58. Organization of the gene for human erythrocyte membrane protein 4.2: structural similarities with the gene for the a subunit of Factor XIII
59. Expression of functional coagulation Factor XIII in Eschericia coli
60. Characterization of the gene for the a subunit of human Factor XIII (plasma transglutaminase), a blood coagulation factor
61. Amino acid sequence of the b subunit of human Factor XIII, a protein composed of ten repetitive segments
62. Isolierung und Charakterisierung des Fibrin-stabilisierenden Faktors aus Menschlichen Thrombozyten
63. Inheritance of deficiency of Fibrin-Stabilizing factor (factor XIII)
64. Factor XIII deficiency: A genetic study of two affected kindreds in Finland
65. A clinical and family study of Factor XIII in a New Zealand family
66. Subunits A and S inheritance in four families with congenital Factor XIII deficiency
67. Congenital Factor XIII deficiency in a neonate
68. Factor XIII levels in five families of patients with inherited Factor XIII deficiency: Support for an autosomal recessive inheritance
69. Hereditary Factor XIII deficiency: report of four families and definition of the carrier state
70. Congenital Factor XIII deficiency: Type I and Type II disease
71. Characterisation of the catalytic subunit of Factor XIII by radioimmunoassay
72. Relationship of the catalytic properties of human plasma and platelet transglutaminase (activated blood coagulation factor XIII) to their subunit structure
73. The subunit composition of Factor XIII proteins in normal and Factor XIII deficiency plasma and serum by line immunoelectrophoresis
74. A familial Factor XIII subunit B deficiency
75. The half-life of Factor XIII in the management of inherited deficiency
76. Effect of pasteurization on the placental Factor XIII concentrate
77. Relationship between Factor XIII subunit-B (B) and injected subunit-A (A) in Factor XIII (XIII) deficient homozygotes and heterozygotes and in normal subjects
78. Factor XIII A is synthesized and expressed on the surface of U937 cells and alveolar macrophages
79. Localization of the gene for coagulation Factor XIIIa chain to chromosome 6 and identification of sites of synthesis
80. Localization of Factor XIII in human tissues using an immunoperoxidase technique
81. Coagulation factor A and B subunits in bone marrow and liver transplantation
82. Biosynthesis of Factor XIII B subunit by human hepatoma cell lines
83. Hemopoietic origin of Factor XIII A subunits in platelets, monocytes and plasma
84. Polymorphism of the A subunit of coagulation Factor XIII in the Pacific region. Description of new phenotypes
85. An extended survey of the genetic polymorphism at the human coagulation Factor XIII A subunit structural locus
86. Genetic polymorphism of the A subunit of human coagulation Factor XIII in Japanese
87. A new method for FXIIIA genetic variants determination using isoelectric focussing in 1M urea. Evidence for three structural loci, FXIIIA1, FXIIIA2 and FXIIIA3
88. Genetic heterogeneity of the B subunit of coagulation Factor XIII: resolution of type 2
89. The use of the serum protein Factor XIIIB (FXIIIB) in parentage testing
90. Genetic polymorphism of the B subunit of human coagulation Factor XIII in Japanese
91. Haplotypes of the coagulation Factor XIIIA subunit locus in normal and deficient subjects
92. Extensive DNA polymorphism at the Factor XIIIa (F13A) locus and linkage to HLA
93. Localization of human coagulation Factor XIIIB subunit gene (F13B) to chromosome bands 1q31-32.1 and restriction fragment polymorphism of the locus
94. The gene for coagulation Factor XIIIa subunit (F13A) is distal to HLA on chromosome 6
95. A structural locus for the coagulation Factor XIIIA (F13A) is located distal to the HLA region on chromosome 6p in man
96. Coagulation Factor XIIIB subunit is encoded by a gene linked to the regulator of complement activation (RCA) gene cluster in man
97. Identification of a point mutation in Factor XIII A subunit deficiency
98. Deficiency of coagulation Factor XIIIA subunit caused by the dinucleotide deletion at the 5′ end of exon III
99. Studies on Factor XIII antigen in congential Factor XIII deficiency. A tentative classification of the disease in two groups
100. Labelling of amine acceptor crosslinking sites of fibrin by transpeptidation
101. The effect of fibrin-stabilizing factor on the subunit structure of human fibrin
102. Chemical and enzymic detection of protein crosslinks: measurement of ε(γ-glutamyl)lysine in fibrin polymerised by Factor XIII
103. ε(γ-glutamyl)lysine in fibrin: lack of crosslink formation in Factor XIII deficiency
104. Isolation, characterisation and location of a donor-acceptor unit from crosslinked fibrin
105. γ-γ-crosslinking sites in human and bovine fibrin
106. Amino acid sequence studies on the α-chain of human fibrinogen Exact location of crosslinking acceptor sites
107. Localisation of a crosslink donor site in the α-chain of human fibrin
108. Effects of crosslinking on the rigidity and proteolytic susceptibility of human fibrin clots
109. Fibrin crosslinks and lysis rates
110. Factor XIII crosslinking and fibrinolytic rates
111. 2-macrogloublin
112. 2-plasmin inhibitor on adsorption of plasminogen to fibrin
113. Inhibitors of the fibrinolytic enzyme system
114. 2-plasmin inhibitor to fibrin. Its comparison with fibronectin crosslinking and its physiological significance
115. 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor
116. Plasmic degradation of crosslinked fibrin. Characterisation of new macromolecular soluble complexes and a model of their structure
117. Plasmin degradation of crosslinked fibrin
118. 2-plasmin inhibitor
119. 2-plasmin-inhibitor deficiency (Miyasato Disease)
120. 2-plasmin inhibitor associated with severe hemorrhagic tendency
121. 2-plasmin inhibitor in three sisters
122. Mild haemostatic problems associated with congenital heterozygous alpha 2-antiplasmin deficiency
123. Intramedullary multiple hematomas in siblings with congenital alpha-2-plasmin inhibitor deficiency - orthopedic surgery with protection by tranexamic acid
124. 2-antiplasmin
125. Differential binding of plasminogen to cross-linked and non-crosslinked fibrins: its significance in hemostatic defect in Factor XIII deficiency
126. Structure of human plasma cold-insoluble globulin and the mechanism of its precipitation in the cold with heparin or fibrin-fibrinogen complexes
127. Specificity of fibronectin-fibrin crosslinking
128. Cross-linking of collagen and fibronectin by Factor XIIIa
129. The subunit structures of human plasma and platelet Factor XIII (fibrin-stabilizing factor)
130. Amino acid sequence of the peptide released from bovine Factor XIII following activation by thrombin
131. Calcium-dependent unmasking of active centre cysteine during activation of fibrin stabilizing factor
132. Titration and subunit localisation of active centre cysteine in fibrinoligase (Thrombin activated Fibrin Stabilizing Factor)
133. Factor XIII: A study using polarisation of fluorescence of the activation of the enzyme by calcium and by substrate
134. Calcium and the assays of human plasma clotting factor XIII
135. Role of calcium ion in the generation of Factor XIII activity
136. Promotion of thrombin-catalysed activation of Factor XIII by fibrinogen
137. The effect of fibrin polymers on thrombin-catalysed plasma Factor XIII formation
138. Characterisation of the fibrin polymer structure that accelerates thrombin cleavage of plasma Factor XIII
139. Studies on the activation of human Factor XIII
140. Thrombin-independent activation of platelet Factor XIII by endogenous platelet acid protease
141. Non-proteolytic activation of cellular protransglutaminase (placental macrophage Factor XIII)
142. Factor 13 deficiency with severe hemorrhagic diathesis
143. Successful pregnancy in a woman with congenital Factor XIII deficiency treated with substitutive therapy
144. Congenital Factor XIII deficiency with treatment of Factor XIII concentrate and normal vaginal delivery
145. A comparative study of the solvents commonly used to detect fibrin stabiliation
146. Factors affecting Factor XIII assay by dansyl cadaverine incorporation
147. Bleeding disorder with abnormal wound healing, acid soluble clots and normal Factor XIII
148. Congenital deficiency of fibrin-stabilizing factor
149. Safety of long-term prophylaxis in inherited Factor XIII deficiency
150. Clinical experience with a pasteurised human plasma concentrate in Factor XIII deficiency
151. Management of patients with congenital deficiency of fibrin stabilising factor (Factor XIII)
152. Factor XIII in pregnancy
153. Diagnostic and genetic studies on fibrin stabilising factor with a new assay based on amine incorporation
154. Type I autoimmune inhibitor of Factor XIII in a patient with congenital Factor XIII deficiency
155. Osteopontin, a substrate for transglutaminase and Factor XIII activity
156. Platelet vinculin: a substrate of activated Factor XIII
157. The influence of fibrin stabilizing factor on the growth of fibroblasts in vitro and wound healing
158. Factor XIII of blood coagulation modulates collagen biosynthesis by fibroblasts in vitro
159. Factor XIIIa-mediated crosslinking of fibronectin in fibroblast cell layers. Crosslinking of cellular and plasma fibronectin and of amino-terminal fibronectin fragments
160. Skin healing and fibrin stabilizing factor blood levels in rabbit fetus
161. Die beschlennigung der frakturheilung durch Faktor XIII
162. Bone healing stimulated by plasma Factor XIII
163. The prophylaxis of post-operative disturbances of wound healing with Factor XIII substitution (results of a double blind study)
164. Factor XIII concentration and wound healing
165. Factor XIII in der Behandlung postoperative-theratierefraktarer wundheilungsstorungen
166. Successful treatment of pseudoarthrosis with human placental Factor XIII concentrate
167. Characterisation of connective tissue cells containing Factor XIII subunit a
168. Bleeding tendency caused by IgG inhibitor to Factor XIII treated successfully by cyclophosphamide
169. Autoimmune antibody (IgG Kansas) against the fibrin stabilizing factor (Factor XIII) system
170. Intracerebral haemorrhage due to acquired Factor XIII inhibitor-successful response to Factor XIII concentrate
171. A unique Factor XIII inhibitor to a fibrin binding site on Factor XIIIA
172. An IgG inhibitor against coagulation Factor XIII: resolution of bleeding after plasma immunoadsorption with staphylococcal protein A
173. A procedure for removing high titer antibodies by extracorporeal protein A-sepharose adsorption in hemophilia
174. An acquired inhibitor of Factor XIII with a qualitative abnormality of fibrin crosslinking
175. Factor XIII deficiency in antibiotic associated pseudomembranous colitis and treatment with Factor XIII concentrate
176. Clinical evaluation of a pasteurised Factor XIII concentrate administration in Henoch-Schönlein purpura
177. Additional substitution of Factor XIII concentrate in the treatment of ulcerative colitis